title: Should neutralizing antibodies be monitored during interferon-beta treatment for multiple sclerosis?
authors.affiliation: Division of Neurology, the Department of Pathology, University of British Columbia, Vancouver, Canada. joel.oger@ubc.ca
authors.forename: Joel
authors.initials: J
authors.lastname: Oger
authors.forename: Ebrima
authors.initials: E
authors.lastname: Gibbs
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood*; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D015166:Monitoring, Immunologic; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D001323:Autoantibodies; D000068576:Interferon beta-1b; D016899:Interferon-beta